Viridian Therapeutics Inc
Change company Symbol lookup
Select an option...
VRDN Viridian Therapeutics Inc
VTN Invesco Trust for New York Investment Grade Municipals
VVR Invesco Senior Income Trust
CLX Clorox Co
SNCY Sun Country Airlines Holdings Inc
NCZ Virtus Convertible & Income Fund II
XPEV Xpeng Inc
PTON Peloton Interactive Inc
PEB Pebblebrook Hotel Trust
VFC VF Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Viridian Therapeutics, Inc. is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company is engaged in developing two product candidates, VRDN-001 and VRDN-002, to treat patients who suffer from thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED.

Closing Price
$26.04
Day's Change
0.77 (3.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
26.48
Day's Low
24.89
Volume
(Above Average)
Volume:
901,245

10-day average volume:
761,030
901,245

Company Profile

Viridian Therapeutics, Inc. is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company is engaged in developing two product candidates, VRDN-001 and VRDN-002, to treat patients who suffer from thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
540.71x
Price/Book (MRQ)
3.81x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

November 2022
Current Month
2.8M
Previous Month
2.3M
Percent of Float
7.35%
Days to Cover
5.8238 Days

Share Information

VRDN is in a share class of common stock
Float
39.7M
Shares Outstanding
40.2M
Institutions Holding Shares
133
92.98%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Tomas Kiselak
  • Jonathan ViolinPres.
  • Kristian HumerCFO
  • Carrie MelvinCOO
  • Lara MeisnerSr.VP

Address

Insider Trading

During the most recent quarter, 426K shares were bought, and 38K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.